banner image

Candriam Equities L Oncology Impact

Marketing Communication. Please refer to the prospectus of the fund and to the key investor information document before making any investment decision. The documents can be obtained free of charge.

Team member image
Rudi Van Den Eynde
Head of Thematic Global Equity
35 Years of experience
  • ISIN
NAV - 07 DEC 2022
USD 259,35
AUM - 07 DEC 2022
USD 1 963 479 874,40
SFDR Category 
Article 9
31 OCT 2022
EAA Fund Sector Equity Healthcare
Morningstar Rating
Morningstar sustainability 
30 SEP 2022
Morningstar Sustainability Rating

Important information

© 2022 Morningstar. All Rights Reserved. The information contained here: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more detailed information about the Morningstar Rating, including its methodology, please go to:

© 2022 Sustainalytics. All Rights Reserved. The information, data, analyses and opinions contained here: (1) includes the proprietary information of Sustainalytics; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product or project; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Sustainalytics is not responsible for any trading decisions, damages or other losses related to it or its use. The use of the data is subject to conditions available at .

About this fund

Candriam Equities L Oncology Impact (hereafter "the fund"), a sub-fund of the Candriam Equities L sicav, invests in listed companies that develop and or sell products and services for the treatment of cancer. The universe includes companies whose products make a difference to patients in the diagnosis, profiling and treatment of cancer. This includes companies that show innovation in surgery, radiation and oncology drugs. The universe ranges from big caps to smaller companies. The investment horizon is 6 years. The fund is managed actively, with reference to the index mentioned on the section "characteristics". For further information about this index and its use, please consult the fund’s key investor information document (KIID).

Principal assets traded:

Shares of companies operating in the field of oncology (study, diagnosis, treatment, etc. of cancer) whose registered offices and/or principal activities are in the whole world.

Investment strategy:

The fund seeks to achieve capital growth by investing in the principal assets traded, outperform the benchmark index and thus have a positive social long term impact, by selecting companies that take on certain societal challenges and that deploy resources in the fight against cancer.

The management team makes discretionary investment choices based on economic/financial analyses but also on Candriam's own social, environmental and governance criteria (ESG).

There are several cornerstones in the selection of securities: a thematic filter, a clinical analysis and a fundamental analysis.

The thematic filter only accepts companies with sufficient exposure to oncology and the battle against cancer in general, for example in areas such as treatments, diagnostic tools, medical equipment and services, and dedicated technologies.

The clinical analysis seeks to evaluate the quality of the available clinical data and to only accept companies considered to be convincing in this regard.

The fundamental analysis focuses on those companies scoring the highest in five criteria:quality of management, growth potential, competitive advantage, value creation and level of indebtedness.

In order to accomplish its social objective, the fonds aims to achieve a performance greater than that of the benchmark index on two corporate indicators (i) expenditure on research and development in relation to the company's stock-market capitalisation and (ii) the level of management qualification by measuring the percentage of management executives having a PhD and this in order to assess the human and financial resources deployed by the companies in the fight against cancer.

The issuers are valued based on an analysis of their activities (in order to assess how these activities help in the fight against cancer) and the stakeholders (how the companies handle the main considerations of the stakeholders such as staff, the environment, etc.). In particular the fund refrains from selecting companies with low ESG ratings and focuses investments on those providing cancer treatment solutions.

Thus, the ESG analysis is integrated into the way the companies are selected, analysed and globally assessed.

The Fund also seeks to exclude investments in companies that do not comply with certain internationally recognised standards and principles, or companies that are particularly exposed to certain controversial activities or that collaborate with countries considered as having highly oppressive regimes.

The ESG analysis depends on the availability, quality and reliability of the under-lying data.  Therefore it may happen that the team cannot select a given stock despite it being attractively priced.

The stock analysis and picking process also entails active involvement, in particular through a dialogue with the companies concerned and by exercising our voting rights in general meetings as a shareholder. For more information, please see the management company's website and/or the prospectus.

The fund may use derivative products both for investment and hedging purposes (hedging against unfavourable future financial events).

Benchmark: MSCI World (Net Return)

The fund is actively managed and the investment process implies referring to a benchmark index.

Definition of the index:

The index measures the performance of the mid and large cap segment in countries with developed markets.

Use of the index:

- as an investment universe.In general, most of the financial instruments in the sub-fund are part of the index.However, investments outside this index are authorised,

- in determining risk levels/risk parameters.

Since the fund is actively managed, it does not have the goal of investing in all components of the index, nor that of investing in the same proportions as the components of this index.In normal market conditions, the expected tracking error of the fund will be significant, i.e. above 4%.This measurement is an estimate of the performance gap between the fund and its benchmark index.The greater the tracking error, the greater the deviations from the benchmark index.The actual tracking error depends in particular on market conditions (volatility and correlations between financial instruments) and may therefore deviate from the tracking error expected.

Redemption of shares: On request, every day, in Luxembourg.

Allocation of income: Reinvestment.

Recommendation: This fund may not be suitable for investors who plan to withdraw their capital within 6 years.


NAV & Performances

Historical values graph



Candriam Equities L Oncology Impact C - Cap - USD

This graph represents the synthetic net asset value of the fund. It is provided for information and illustrative purposes only. The synthetic net asset value is obtained by a recalculation of the values of the fund’s assets by leveling out the effect of securities transactions (split, coupon, dividend distribution...) in order to reflect the real performance of the fund share or unit. Data may be rounded for convenience. Data expressed in a currency other than that of the investor's country of residence is subject to exchange rate fluctuations, with a positive or negative impact. Gross performance may be impacted by commissions, fees and other expenses.


This table shows the fund's performance as the percentage of annual loss or gain over the years shown.

Actuarial Yield

  1 year 3 years
Share class -14.94 % 10.07 %
Benchmark -18.48 % 6.05 %
Difference 3.54 % 4.02 %

Annual return over the last 10 years (%)

The performances of the years prior to the material change have been blurred on the graph.
  2019 2020 2021
Share class 40,34 % 31,32 % 2,50 %
Benchmark 23,24 % 13,12 % 21,82 %
Difference 17,09 % 18,20 % -19,32 %

Excluding fees/taxes: taxes are not part of the performance calculation

Additional information

Past performance is not a reliable indicator of future performances. Markets could develop very differently in the future.
It can help you assess how the fund has been managed in the past.

The returns listed above are provided on the basis of the Net Asset Value (NAV), net of commissions and reinvested income. All management fees and commissions are included in the calculation of past performance except for any entry and exit charges. Taxes are not included in the calculation of returns. The value or price converted into euros may be reduced or increased depending on fluctuations in the exchange rate. The fund is not a guaranteed investment. The NAVs are net of fees and are provided by the accounting department and the benchmark by the official providers.

Market developments (currency conversion, coupon, split, …) have an influence on the chart. This graph is provided for information purposes only and does not precisely illustrate the evolution of the fund's net assets. Data may be rounded for convenience. Data expressed in a currency other than that of the investor's country of residence is subject to exchange rate fluctuations, with a positive or negative impact. Gross performance may be impacted by commissions, fees and other expenses


Fund Characteristics

Fund name
Candriam Equities L Oncology Impact
Candriam Equities L
Legal Form
Sub-fund of a SICAV under Luxembourg law
Fund type
SFDR Category
Article 9
Creation Date
Term of the fund
The fund has no limited term
Domicile Country
Management Company
Depository Bank
CACEIS Bank, Luxembourg Branch
Transfer Agent
CACEIS Bank, Luxembourg Branch
Recommended investment horizon
6 years
Swing Pricing System
Swing Pricing Description
Swing Pricing is a mechanism by which the net asset value is adjusted upwards (or downwards) if the change in liabilities is positive (or negative) in such a way as to reduce for existing investors the portfolio restructuring costs linked to subscription/ redemption movements in the fund. On valuation days where the difference between the amount of subscriptions and the amount of redemptions of a sub-fund (i.e. net transactions) exceeds a threshold set beforehand by the Board of Directors, the latter shall be entitled to:
- value the net asset value by adding to the assets (in the case of net subscriptions) or deducting from assets (at net redemptions) a fixed percentage of the fees corresponding to market practices and reflecting the fees and/or conditions of liquidity when buying or selling securities; - value the securities portfolio on the basis of bid or ask prices;
- assess the net asset value by setting a level of spreads representative of the relevant market;
- The dilution mechanism must not exceed 2% of the net asset value, except in exceptional circumstances, as in the event of a sharp decrease in liquidity, which would then be detailed for the sub-fund concerned in the annual (semi-) annual report of the SICAV.

Tax, Charges & Fees

Management fees (max)
1.60 %
3.50 %
0.00 %
OCF Date
Last OCF
1.94 %


C - Cap
Bloomberg Ticker
Morningstar Ticker
First NAV Date


NAV Date
NAV Calculation Day
Frequency valuation
Subscription Cut off
D 12:00
Redemption Cut off
D 12:00

The corresponding time zone is the one associated with the fund's domicile.


Lower riskHigher risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially lower return Potentially higher return
The risk and reward profile is an indicator with a rating ranging from 1 to 7 and corresponds to increasing levels of risk and return. The methodology for calculating this regulatory indicator is available in the KIID.
The risk category is calculated on the basis of historical performance and is not necessarily a reliable indicator of the fund’s future risk profile.
It may change in the future and is not guaranteed.
The lowest category does not mean no risk.
Main Risks

Concentration risk: This risk is related to a significant concentration of investments in a specific asset class or certain markets. The greater the diversification of the fund is, the lesser the concentration risk will be.

Currency risk: Funds may hold exposure to a currency different from its valuation currency. Changes in the exchange rate of this currency may negatively affect the value of assets in the portfolio.

Derivative risk: Derivatives are investments whose value depends on (or is derived from) the value of an underlying instrument, such as a security, asset, reference rate or index. Derivative strategies often involve leverage, which may exaggerate a loss, potentially causing the Sub-Fund to lose more money than it would have lost had it invested in the underlying instrument. Using derivatives may result in a higher portfolio volatility related to this underlying asset and an increase of the counterparty risk.

Emerging market risk: These markets are characterized by higher volatility issues and a lower liquidity because of legal, political and structural matters. Market movements can be stronger and faster on emerging markets than on “developed markets”, which can lead to a substantial decline in the net asset value in the event of the adverse movements relative to the positions taken.

Equity Risk: Some funds may be exposed to equity market risk through direct investment (through transferable securities and/or derivative products), meaning submitted to the positive or negative evolution of stock exchanges. These evolutions can be huge and be mainly driven by expectations relative to macro-economy and company results, speculation and irrational factors (including trends, opinions or rumours).

ESG Investment Risk: ESG investment risk refers to the risks arising from the inclusion of ESG factors in the management process, such as the exclusion of activities or issuers and the inclusion of sustainability risks in the selection and/or allocation of issuers in the portfolio.

Liquidity risk: lt occurs when a portfolio position cannot be sold, liquidated or closed at a limited cost and within a sufficiently short time, which jeopardizing the fund's ability to comply at any time with its obligations to redeem the shares of investors at their request.

Risk of loss of capital: Investors are advised that any capital they invest is not guaranteed and that they may therefore not receive back the full amount invested. They may thus suffer a loss.

Other Risks
Conservation risk Counterparty Risk Delivery risk Legal risk Operational risk Risk of conflict of interest Sustainability Risk

Risk and reward indicators 2022-10-31

18.95 %
18.74 %
Tracking error
12.22 %
Sharpe Ratio
Information ratio
Price Earning Ratio
19.40 %
16.58 %
36.31 %
19.60 %
Price to Book Value
5.22 %
16.58 %
Dividend Yield
1.22 %
2.26 %
Total Net Exposure
96.29 %
100.00 %
Active share
94.19 %
Number of Issues


SFDR Category: Article 9


This fund has a sustainable investment objective. It invests in economic activities contributing to an environmental and/or social objective. To achieve this objective, the management team makes discretionary investment choices based on an economic/financial analysis process and an internal analysis of environmental, social and governance (ESG) criteria.

a. ESG selection criteria:

The internal analysis of ESG criteria consists in selecting issuers:
• the best positioned to meet the challenges of sustainable development;
• that comply with the principles of the United Nations Global Compact (i.e. human rights, labour law, the environment, anti-corruption), and which are therefore less exposed to the risks associated with these themes; and
• that are not engaged in controversial activities such as armament (securities of a company whose activity consists of manufacturing, the use or possession of anti-personnel mines, cluster bombs and/or depleted uranium weapons), tobacco, thermal coal;

b. Selection methodology:

The companies selected by the management company are subject to a dual analysis:
• Analysis of their activity to assess their alignment with the major challenges of sustainable development. For example, regarding the transition to a circular economy, the management company will consider a company producing recycled steel to be more sustainable than a company producing steel exclusively from iron ore; and
• Analysis of how the company manages players interacting with the company: its employees, its customers, its shareholders, its suppliers and the environment. Here too, the management company will favour companies that adopt the most sustainable practices given their sector. For example, with regard to relations with its clients, the management company will favour pharmaceutical companies with balanced pricing practices and commercial policies. Similarly, with regard to relations with their employees, the management company attaches great importance to the fight against discrimination and compliance with social standards.

c. A team of ESG analysts is responsible for assessing the selection criteria:

The analysis and selection of sustainable investments is carried out by a dedicated team of ESG analysts within Candriam. This team is made up of specialists whose mission is to analyse the exposure of companies and governments to the risks and opportunities associated with sustainable development. Selection criteria are expected to evolve over time, based on advances in ESG research and changes in company practices.

For more information on the sustainability of our investments and the integration of sustainability risks, please refer to Candriam’s transparency policies and codes and SFDR Article 9 fund sustainability information (available on our website: and the fund prospectus (available on our website

* SFDR is the acronym given to Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on the publication of sustainability information in the financial services sector


France: ISR

Belgium: Towards sustainability


References to rankings, awards and/or ratings are not indicators of the future performance of the funds or the asset manager.

Switzerland 2022 Lipper Fund Awards

Event Date
Equity Sector Healthcare - 3 years
Website of organizere

France 2022 Lipper Fund Awards

Event Date
Equity Sector Healthcare - 3 years
Website of organizere

Other important information

This is a marketing communication. Please refer to the prospectus of the funds and to the key information document before making any investment decision. This marketing communication does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.
Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.
In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment’s principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.
Candriam consistently recommends investors to consult via our website the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value (“NAV) of the funds. Investor rights and complaints procedure, are accessible on Candriam’s dedicated regulatory webpages This information is available either in English or in local languages for each country where the fund’s marketing is approved.
According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.
Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Find it fast

Get information faster with a single click

Get insights straight to your inbox